Featured Research

from universities, journals, and other organizations

Men With Advanced, Incurable Prostate Cancer Can Benefit From Docetaxel

Date:
October 13, 2004
Source:
University Of Toronto
Summary:
An international study led by a Canadian researcher shows that men with advanced, incurable prostate cancer can survive an average of three months longer and face less symptoms when offered a new treatment for prostate cancer.

Toronto (October 6, 2004) – An international study led by a Canadian researcher shows that men with advanced, incurable prostate cancer can survive an average of three months longer and face less symptoms when offered a new treatment for prostate cancer.

Published in tomorrow's issue of The New England Journal of Medicine, the study involved 24 countries and over two years tracked more than 1,000 patients with advanced hormone-refractory prostate cancer. The patients were randomly divided into three groups, with one group receiving the standard chemotherapy (mitoxantrone), while the other two groups received docetaxel either every three weeks or weekly. All three groups received low daily doses of prednisone. Researchers looked at several outcome measures – survival, pain relief, improved quality of life, and the amount of PSA in the patients' blood, which indicates the amount of cancer present in the body. In all these measures, men who received docetaxel administered every three weeks did better than those who received mitoxantrone, and it improved survival by an average of three months. There was no significant difference in survival between those patients receiving docetaxel weekly and those receiving mitoxantrone.

"The new treatment of docetaxel results in many patients feeling better and living a few months longer," said Dr. Ian Tannock, the study's lead author and medical oncologist at Princess Margaret Hospital, senior scientist with Ontario Cancer Institute, and professor with the University of Toronto. "As a result, we are recommending docetaxel every three weeks with daily prednisone as the new standard of treatment for many patients with advanced hormone-refractory prostate cancer."

Prostate cancer is the most common cancer in men. One in eight Canadian men will develop the disease during their lifetime, and most cases are diagnosed in men over the age of 65. Initially, prostate cancer may be treated by surgery, removing the prostate gland, or by radiation therapy. In some cases, the cancer becomes metastatic, spreading to other parts of the body. It is then usually treated by measures that modify the body's hormones, since prostate cancer cells are stimulated to grow by male hormones such as testosterone. However, the cancer may eventually become resistant to hormonal treatment and patients might then benefit from chemotherapy. Docetaxel works by interfering with the cells' ability to divide. Currently used in some breast cancer and lung cancer patients, its side effects include changes in nails, tiredness, tingling and loss of sensation in fingers and toes. Docetaxel has been approved by the U.S. Food and Drug Administration.

###

This research was supported in part by Aventis, the company that manufactures Docetaxel.


Story Source:

The above story is based on materials provided by University Of Toronto. Note: Materials may be edited for content and length.


Cite This Page:

University Of Toronto. "Men With Advanced, Incurable Prostate Cancer Can Benefit From Docetaxel." ScienceDaily. ScienceDaily, 13 October 2004. <www.sciencedaily.com/releases/2004/10/041007085048.htm>.
University Of Toronto. (2004, October 13). Men With Advanced, Incurable Prostate Cancer Can Benefit From Docetaxel. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2004/10/041007085048.htm
University Of Toronto. "Men With Advanced, Incurable Prostate Cancer Can Benefit From Docetaxel." ScienceDaily. www.sciencedaily.com/releases/2004/10/041007085048.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins